Abstract
A drug for metastatic breast cancer should not be used in the NHS in England because it is not effective enough to justify its £90 000 (€110 000; $150 000)...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
